Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,812,605.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $506.59, for a total value of $4,812,605.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $164,359,579.37. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $521.00 on Friday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The stock’s fifty day moving average price is $533.74 and its two-hundred day moving average price is $537.53. The company has a market cap of $22.35 billion, a PE ratio of 18.64, a P/E/G ratio of 1.79 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the firm earned $6.41 EPS. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several research analyst reports. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Toth Financial Advisory Corp boosted its position in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the period. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter valued at approximately $26,000. Fiduciary Financial Advisors acquired a new position in United Therapeutics in the 2nd quarter valued at approximately $30,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.